BRPI0513007A - terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b - Google Patents

terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b

Info

Publication number
BRPI0513007A
BRPI0513007A BRPI0513007-7A BRPI0513007A BRPI0513007A BR PI0513007 A BRPI0513007 A BR PI0513007A BR PI0513007 A BRPI0513007 A BR PI0513007A BR PI0513007 A BRPI0513007 A BR PI0513007A
Authority
BR
Brazil
Prior art keywords
treatment
cell lymphoma
combination therapy
antibody combination
antibody
Prior art date
Application number
BRPI0513007-7A
Other languages
English (en)
Inventor
Werner Krause
Joachim Kalmus
Jens Kuhlamann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0513007A publication Critical patent/BRPI0513007A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TERAPIA DE COMBINAçãO COM ANTICORPO ANTI-CD20 MARCADO RADIOATIVAMENTE NO TRATAMENTO DE LINFOMA DE CéLULA B. A presente invenção refere-se a um processo de tratamento de linfoma de células B compreende a administração a um paciente de um regime quimioterapêutico, seguido pelo tratamento com um anticorpo anti-CD20 marcado radioativamente, em que no momento do dito tratamento com o dito anticorpo marcado radioativamente o dito paciente não é refratário ao dito regime quimioterapêutico e não sofreu reincidência.
BRPI0513007-7A 2004-07-09 2005-07-07 terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b BRPI0513007A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58641404P 2004-07-09 2004-07-09
PCT/EP2005/007213 WO2006005477A1 (en) 2004-07-09 2005-07-07 Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma

Publications (1)

Publication Number Publication Date
BRPI0513007A true BRPI0513007A (pt) 2008-04-22

Family

ID=34972426

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513007-7A BRPI0513007A (pt) 2004-07-09 2005-07-07 terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b

Country Status (13)

Country Link
US (2) US20060029543A1 (pt)
EP (1) EP1765399A1 (pt)
JP (2) JP2008505148A (pt)
KR (1) KR101250127B1 (pt)
AU (1) AU2005261923B2 (pt)
BR (1) BRPI0513007A (pt)
CA (1) CA2568526C (pt)
IL (1) IL179636A (pt)
MX (1) MX2007000327A (pt)
NO (1) NO344366B1 (pt)
RU (1) RU2394596C2 (pt)
WO (1) WO2006005477A1 (pt)
ZA (1) ZA200701158B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8061104B2 (en) 2005-05-20 2011-11-22 Valinge Innovation Ab Mechanical locking system for floor panels
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
US11055552B2 (en) * 2016-01-12 2021-07-06 Disney Enterprises, Inc. Systems and methods for detecting light signatures and performing actions in response thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
WO2000059473A1 (en) * 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
RU2004127458A (ru) * 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Анти-cd20 антитела, их гибридные белки и способы их использования
WO2004047612A2 (en) 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis

Also Published As

Publication number Publication date
US20060029543A1 (en) 2006-02-09
KR101250127B1 (ko) 2013-04-02
AU2005261923B2 (en) 2010-11-18
IL179636A0 (en) 2007-05-15
AU2005261923A1 (en) 2006-01-19
NO20070763L (no) 2007-02-08
JP2008505148A (ja) 2008-02-21
CA2568526A1 (en) 2006-01-19
IL179636A (en) 2013-09-30
JP2014080429A (ja) 2014-05-08
EP1765399A1 (en) 2007-03-28
KR20070042527A (ko) 2007-04-23
JP6034314B2 (ja) 2016-11-30
NO344366B1 (no) 2019-11-18
RU2007104839A (ru) 2008-08-20
ZA200701158B (en) 2008-09-25
CA2568526C (en) 2015-11-03
MX2007000327A (es) 2007-03-12
US20190112383A1 (en) 2019-04-18
RU2394596C2 (ru) 2010-07-20
WO2006005477A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
NZ604031A (en) Methods of treatment of pancreatic cancer
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
BRPI0821441A8 (pt) Processo de fabricação de uma peça metálica reforçada de fibras cerãmicas
NZ594950A (en) Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
TR200000157T2 (tr) Nitrik oksit rhinovirüsün bulaşmasını önler.
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
BRPI0507194A (pt) processo para reduzir o conteúdo e cianeto de hidrogênio em misturas compreendendo penteno-nitrilas e cianeto e hidrogênio, e, uso de 1,3-butadieno
WO2007149586A3 (en) Anti-c35 antibodies for treating cancer
NO20070763L (no) Kombinasjonsterapi med radiomerket anti-CD20-antistoff i behandlingen av B-cellelymfom
BRPI0507463A (pt) uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine
Stabholz et al. Using the PerioChip in treating adult periodontitis: an interim report.
Xiao-Mian et al. Study of 99mTc-TRODAT-1 imaging on human brain with children autism by single photon emission computed tomography.
Miller Can family support improve stroke recovery?
Plopski History of the Introduction of Lithium into Medicine and Psychiatry-Birth of Modern Psychopharmacology 1949
Zhang et al. Development of OMZs in the East Tropical Pacific during the mid-late Miocene due to the CAS shoaling
Severmann et al. What can Fe Isotopes in Anoxic Environments Tell us About the Rise of Oxygen in the Coupled Land-Ocean-Atmosphere System?-Clues From the Black Sea
Salim Safir $ B\to K^*\ell^+\ell^-\big (\rho\ell\nu_ {\ell}\big) $ helicity analysis in the LEET
White et al. Automated radiation hard ASIC design tool
Szabó Nitric oxide, peroxynitrite and poly (adpribose) synthetase activation: role in the suppression of cellular energetics
Assembly Concerning Automatic Termination of Child Support.
Hanvey Self-Portrait
Deutsch et al. Identification and Quantification of Diffuse Nitrogen Inputs Into a River System Using Stable Isotopes of Nitrogen and Oxygen in Nitrate
Jinuntuya et al. Isotopologue fractionation during nitrous oxide reduction in soil

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL